河北医科大学学报 ›› 2024, Vol. 45 ›› Issue (9): 1007-1011.doi: 10.3969/j.issn.1007-3205.2024.09.004

• • 上一篇    下一篇

尼麦角林与吲哚布芬联合应用治疗急性脑梗死的效果研究

  

  1. 南京医科大学附属淮安第一医院药学部，江苏 淮安 223300

  • 出版日期:2024-09-25 发布日期:2024-09-30
  • 作者简介:张娜（1986-），女，江苏淮安人，南京医科大学附属淮安第一医院药剂师，理学学士，从事药学方面研究。
  • 基金资助:
    江苏省自然科学基金(BK20191212)

Effect of niergoline combined with indobuprofen in the treatment of acute cerebral infarction

  1. Department of Pharmacy, the First Affiliated Hospital of Huaian, Nanjing Medical University, Jiangsu Province, Huaian 223300, China

  • Online:2024-09-25 Published:2024-09-30

HTML

PDF (PC)

85

摘要： 目的 研究尼麦角林与吲哚布芬联合应用治疗急性脑梗死的效果。
方法 选择南京医科大学附属淮安第一医院收治的急性脑梗死患者122例，以随机数字表法分成研究组（n=61）与对照组（n=61）。2组均接受基础治疗，对照组在此基础上给予吲哚布芬治疗，研究组在对照组的基础上给予尼麦角林治疗。2组均治疗14 d。比较2组美国国立卫生研究所卒中量表（National Institute of Health Stroke Scale，NIHSS）评分、改良Rankin量表（Modified Rankin Scale，mRS）评分、临床疗效、血清心型脂肪酸结合蛋白（heart-type fatty acid-binding protein，H-FABP）、β-肌动蛋白（β-actin）、胰岛素样生长因子1（insulin like growth factor-1，IGF-1）水平、血浆比黏度、全血比高切黏度、血浆纤维蛋白原、全血比低切黏度及安全性。
结果 治疗后，2组NIHSS评分、mRS评分均降低，研究组低于对照组（P＜0.05）。研究组总有效率（91.80%）比对照组（77.05%）高（P＜0.05）。治疗后，2组血清H-FABP、β-actin水平均降低，研究组低于对照组（P＜0.05）；治疗后，2组血清IGF-1水平均升高，研究组高于对照组（P＜0.05）。治疗后，2组血浆比黏度、全血比高切黏度、血浆纤维蛋白原及全血比低切黏度均降低，研究组低于对照组（P＜0.05）。2组不良反应总发生率比较差异无统计学意义（P＞0.05）。
结论 尼麦角林与吲哚布芬联合应用治疗急性脑梗死效果确切，可改善患者神经功能、血清生化指标及血液流变学，且不良反应少。


关键词: 脑梗死, 尼麦角林, 吲哚布芬

Abstract: Objective To study the effect of niergoline combined with indobuprofen in the treatment of acute cerebral infarction (ACI). 
Methods A total of 122 patients with ACI admitted to the First Affiliated Hospital of Huaian were selected and divided into research group (n=61) and control group (n=61) by random number table method. Both groups received basic treatment, the control group was additionally given indobuprofen, and the research group was additionally given niergoline. Both groups were treated for 14 d. National Institute of Health Stroke Scale (NIHSS) score, Modified Rankin Scale (mRS) score, clinical efficacy, serum levels of heart-type fatty acid-binding protein (H-FABP), β-actin (β-actin), insulin-like growth factor-1 (IGF-1), plasma specific viscosity, whole blood high shear viscosity, plasma fibrinogen, whole blood low shear viscosity and safety of the two groups were compared. 
Results After treatment, both groups showed a decrease in NIHSS scores and mRS scores, with the research group being lower than the control group (P＜0.05). The total effective rate of the research group (91.80%) was higher than that of the control group (77.05%) (P＜0.05). After treatment, the levels of serum H-FABP and β-actin in both groups decreased, with the research group being lower than the control group (P＜0.05). After treatment, the serum IGF-1 levels in both groups increased, with the research group being higher than the control group (P＜0.05). After treatment, both groups showed a decrease in plasma specific viscosity, whole blood high shear viscosity, plasma fibrinogen, and whole blood low shear viscosity, with the research group being lower than the control group (P＜0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P＞0.05). 
Conclusion Niergoline combined with indobuprofen is effective in the treatment of ACI, and can improve the neurological function, serum biochemical indexes and hemorheology, and has few adverse reactions. 


Key words: brain infarction, nicergoline, indobuprofen

版权所有 © 《河北医科大学学报》编辑部
本系统由北京玛格泰克科技发展有限公司设计开发